Targeting Malignant Brain Tumors with Antibodies

Area of Science:

• Neuroscience
• Immunology
• Oncology

Background:

• Antibodies are effective therapeutics but struggle to cross the blood-brain barrier (BBB).
• Targeting brain diseases like gliomas is hindered by the BBB's restrictive nature.
• Conventional antibody delivery strategies are insufficient for accessing brain tissue.

Purpose of the Study:

• To review novel antibody therapeutic approaches for brain tumors, particularly malignant gliomas.
• To summarize various platforms for delivering antibodies across the BBB.
• To discuss the potential drawbacks and recent clinical progress of these strategies.

Main Methods:

• Review of existing literature on antibody delivery systems for brain diseases.
• Exploration of platforms including liposomes, nanoparticles, cell-penetrating peptides (CPPs), and cell-based systems.
• Analysis of the "Trojan horse" method utilizing receptor-mediated transcytosis (RMT) and bispecific antibodies.
• Examination of stem cell (SC)-based delivery, including mesenchymal stem cells (MSCs) and neural stem cells (NSCs).
• Discussion of adoptive T-cell therapies like chimeric antigen receptor-T cells (CAR-Ts).

Main Results:

• Various platforms like CPPs, liposomes, and nanoparticles show potential for antibody delivery across the BBB.
• Bispecific antibodies leveraging RMT offer a targeted approach to cross the BBB.
• Stem cells (SCs), particularly MSCs and NSCs, demonstrate tumor tropism and BBB-crossing capabilities for drug delivery.
• CAR-T cell therapy represents an emerging cell-based strategy for glioma treatment.

Conclusions:

• Innovative antibody delivery platforms are crucial for overcoming BBB limitations in treating brain diseases.
• Cell-based therapies and engineered antibodies show significant promise for targeting brain tumors.
• Ongoing clinical trials are advancing the development of antibody therapeutics for brain conditions.